PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[king oil]

I took a look at the average cost for 2 competing treatments -- Fabrazyme and Galafold. They each cost anywhere from $200,000 to $300,000 per year, depending on the country (lower end in Europe and higher end in the US).

Assuming approval, it will be interesting to see what PLX's strategy is for pricing PRX-102. Do they charge more because the treatment is superior to existing, or less to give insurance companies an incentive to cover it vs. the other treatments?

Or perhaps it's entirely up to Chiesi to set the prices.

https://www.reuters.com/article/us-amicus-fda/amicus-sets-315000-price-for-new-fabry-disease-treatment-idUSKBN1KY1E8